{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:12:45Z","timestamp":1793293965074,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>TAFRO syndrome is a systemic inflammatory disease of unknown aetiology. It is characterised by thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly. Herein, we report the case of a 60-year-old male with TAFRO syndrome. A few weeks after the patient developed an intermittent fever, he presented to our hospital with diarrhoea, abdominal distension, and whole-body oedema (face, extremities, and abdomen). Autoantibody and lip biopsy findings supported the diagnosis of primary Sj\u00f6gren\u2019s syndrome. High-dose steroids and tocilizumab were used to treat his refractory thrombocytopenia and ascites. However, systemic inflammation and renal dysfunction did not improve, resulting in temporary haemodialysis. Eventually, combined B-cell immunomodulation therapy with rituximab and belimumab ameliorated the patient\u2019s symptoms. About 16\u2009weeks after discharge, the overall condition of the patient had improved. The TAFRO syndrome may be a severe manifestation of primary Sj\u00f6gren\u2019s syndrome. Considering the immunological context, combined B-cell immunomodulation therapy provides new insights into improving this life-threatening disease and enables rapid steroid tapering.<\/jats:p>","DOI":"10.1093\/mrcr\/rxad020","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T07:16:18Z","timestamp":1681629378000},"page":"475-479","source":"Crossref","is-referenced-by-count":7,"title":["Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sj\u00f6gren\u2019s syndrome: A case report"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8398-8007","authenticated-orcid":false,"given":"Mitsuru","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Daido Hospital , Nagoya city, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Haji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Daido Hospital , Nagoya city, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirai","family":"Hozumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Daido Hospital , Nagoya city, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Amari","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Daido Hospital , Nagoya city, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukina","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Daido Hospital , Nagoya city, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Daido Hospital , Nagoya city, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Daido Hospital , Nagoya city, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Okada","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Center, St. Luke\u2019s International Hospital , Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"2023061920012663900_R1","first-page":"320","article-title":"Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly","volume":"51","author":"Takai","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"2023061920012663900_R2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3960\/jslrt.53.57","article-title":"Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012)","volume":"53","author":"Kawabata","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"2023061920012663900_R3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JBM.S127822","article-title":"TAFRO syndrome: current perspectives","volume":"9","author":"Sakashita","year":"2018","journal-title":"J Blood Med"},{"key":"2023061920012663900_R4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome","volume":"111","author":"Masaki","year":"2020","journal-title":"Int J Hematol"},{"key":"2023061920012663900_R5","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103137","article-title":"TAFRO syndrome: a severe manifestation of Sj\u00f6gren\u2019s syndrome? A systematic review","volume":"21","author":"Grange","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2023061920012663900_R6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/14397595.2015.1120389","article-title":"TAFRO syndrome successfully treated with tocilizumab: a case report and systematic review","volume":"28","author":"Sakai","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023061920012663900_R7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/14397595.2016.1206243","article-title":"A case of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, successfully treated with corticosteroid and cyclosporine","volume":"29","author":"Takasawa","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023061920012663900_R8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2177\/jsci.39.64","article-title":"Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy","volume":"39","author":"Hiramatsu","year":"2016","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"2023061920012663900_R9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"2023061920012663900_R10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2023061920012663900_R11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.22458","article-title":"Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"56","author":"Daridon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023061920012663900_R12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"2023061920012663900_R13","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kev005","article-title":"Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"54","author":"Pontarini","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2023061920012663900_R14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2023061920012663900_R15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2169\/internalmedicine.7976-21","article-title":"Bilateral adrenal infarctions as an initial manifestation of TAFRO syndrome: a case report and review of the literature","volume":"61","author":"Yonezaki","year":"2022","journal-title":"Intern Med"},{"key":"2023061920012663900_R16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13730-018-0338-x","article-title":"Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome","volume":"7","author":"Ozeki","year":"2018","journal-title":"CEN Case Rep"},{"key":"2023061920012663900_R17","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1574-9","article-title":"TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review","volume":"20","author":"Nagayama","year":"2019","journal-title":"BMC Nephrol"},{"key":"2023061920012663900_R18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3960\/jslrt.21037","article-title":"International definition of iMCD-TAFRO: future perspectives","volume":"62","author":"Nishimura","year":"2022","journal-title":"J Clin Exp Hematop"},{"key":"2023061920012663900_R19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2010.05.006","article-title":"B-cell tolerance breakdown in Sj\u00f6gren\u2019s syndrome: focus on BAFF","volume":"9","author":"Varin","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2023061920012663900_R20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.immuni.2020.04.015","article-title":"Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA","volume":"52","author":"Soni","year":"2020","journal-title":"J Immunity"},{"key":"2023061920012663900_R21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00277-022-04762-6","article-title":"Castleman disease and TAFRO syndrome","volume":"101","author":"Masaki","year":"2022","journal-title":"Ann Hematol"},{"key":"2023061920012663900_R22","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1084\/jem.20170580","article-title":"B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity","volume":"214","author":"Arkatkar","year":"2017","journal-title":"J Exp Med"},{"key":"2023061920012663900_R23","doi-asserted-by":"crossref","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon \u03b3-induced protein 10 kDa is associated with TAFRO syndrome","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"key":"2023061920012663900_R24","article-title":"Elevated cytokine levels in tears and saliva of patients with primary Sj\u00f6gren\u2019s syndrome correlate with clinical ocular and oral manifestations","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"2023061920012663900_R25","article-title":"The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome","volume":"215","author":"Kurose","year":"2019","journal-title":"Pathol Res Pract"},{"key":"2023061920012663900_R26","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"key":"2023061920012663900_R27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023061920012663900_R28","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06874-w","article-title":"Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial","volume":"23","author":"van Schaik","year":"2022","journal-title":"Trials"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxad020\/50267418\/rxad020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/475\/50646409\/rxad020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/475\/50646409\/rxad020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T20:06:02Z","timestamp":1687205162000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/7\/2\/475\/7123800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,15]]},"published-print":{"date-parts":[[2023,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxad020","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,4,15]]}}}